Quintrio
Home

PHARMACEUTICAL PREPARATIONS

Pyxis Oncology, Inc. Common Stock

PYXS

Pyxis Oncology Inc is a clinical-stage oncology company focused on developing therapies for patients with solid tumors, with an initial emphasis on head and neck squamous cell carcinoma. Its product candidate, micvotabart pelidotin (MICVO, formerly PYX-201), is an investigational antibody-drug conjugate that targets extradomain-B fibronectin (EDB+FN), a component of the tumor extracellular matrix that is expressed in tumors and minimally present in normal tissues. MICVO consists of a fully human monoclonal antibody linked to a microtubule inhibitor payload, designed to bind within the tumor microenvironment and release its payload to kill cancer cells directly, affect nearby cells through a bystander effect, and induce immunogenic cell death, supporting enhanced anti-tumor activity.

Last trade $1.41
Day change -$0.005 (-0.35%)
Day range $1.36 – $1.55
Volume 1,122,754
Market cap $169M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$168.65M
Price / earnings
—
Price / book
4.08×
Price / sales
15.28×
EV / sales
14.93×
EV / EBITDA
-1.93×

Profitability

Earnings per share
-$0.72
Return on assets
-112.95%
Return on equity
-209.85%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0×
Current ratio
2.96×
Quick ratio
2.96×
Cash ratio
0.19×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$70.93M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for PYXS, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$0$0$0$11.04M$0$2.82M$0$0
Cost of revenue$0$0$0$2.39M$0$0$0$0
Gross profit$0$0$0$8.65M$0$2.82M$0$0
Selling, general and administrative$3.97M$9.93M$4.38M$5.23M$5.65M$5.44M$5.87M$5.08M
Research and development$16.56M$16.06M$19.98M$21.71M$17.81M$17.13M$17.04M$14.02M
Total operating expenses$20.52M$25.99M$24.36M$26.95M$23.46M$22.57M$22.91M$40.07M
Operating income-$20.52M-$25.99M-$24.36M-$18.3M-$23.46M-$19.75M-$22.91M-$40.07M
Interest expense$0$0$0$0$0$0$0$0
Income before taxes-$19.98M-$25.35M-$23.27M-$17M-$22M-$18.07M-$21.16M-$37.74M
Income taxes$0$0$0$1.1M$0$283K$0-$2.16M
Net income-$19.98M-$25.35M-$23.27M-$18.11M-$22M-$18.35M-$21.16M-$35.57M
Net income attributable to common shareholders-$19.98M-$25.35M-$23.27M-$18.11M-$22M-$18.35M-$21.16M-$35.57M
EBITDA-$20.22M-$25.69M-$23.9M-$15.4M-$22.93M-$19.22M-$22.36M-$18.56M
Basic earnings per share-$0.24-$0.40-$0.37-$0.29-$0.35-$0.30-$0.35-$0.58
Diluted earnings per share-$0.24-$0.40-$0.37-$0.29-$0.35-$0.30-$0.35-$0.58

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
GlobeNewswire Inc.

Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, June 28, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, reported today that Pyxis Oncology’s Compensation Committee of the Board of Directors granted restricted stock units with respect to an aggregate of 89,530 shares of Pyxis Oncology’s common stock and stock options to purchase an aggregate of 111,913 shares of Pyxis Oncology’s common stock to five newly hired employees. The awards were granted under the Pyxis Oncology, Inc. 2022 Inducement Plan with a grant date of June 28, 2024, as an inducement material to the new employee entering employment with Pyxis Oncology, in accordance with Nasdaq Listing Rule 5635(c)(4).

GlobeNewswire Inc.

Pyxis Oncology Expands Board of Directors with Appointment of Michael A. Metzger

BOSTON, June 10, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: “PYXS”), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, today announced the appointment of Michael A. Metzger to its Board of Directors, effective June 10, 2024. Mr. Metzger has over 25 years of experience in the biopharmaceutical sector, currently serving as Chief Executive Officer and as a member of the Board of Directors of Syndax Pharmaceuticals, Inc. (Nasdaq: SNDX) since 2015.

GlobeNewswire Inc.

Pyxis Oncology to Participate in a Fireside Chat at the Jefferies Global Healthcare Conference

BOSTON, May 30, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, announced today that Lara S. Sullivan, M.D., President and Chief Executive Officer, will participate in a fireside chat on Thursday, June 6, 2024 at 9:00 AM Eastern Time at the Jefferies Global Healthcare Conference in New York City, where members of management will also host investor one-on-one meetings.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.